 pharmacontrol ltpharo acquires revco unit pharmacontrol corp acquired private formulations ltrevco ds mln dlrs cash 13550000 dlr promissory note warrants buy 200000 pharmacontrol common shares pharmacontrol purchase price financed mln dlrs working capital secured institutional financing company betweenm 11550000 dlrs 12550000 dlrs principal amount revco note accrued interest payable june 30 balance payable years pharmacontrol expects make payment due revco proceeds proposed offering units consisting convertible subordinated debenturers common stock file securities exchange commission closing public offering company expects secured institutional financing increase total 12 mln dlrs private formulations primarily engaged manufacture distribution vitamins private label overthecounter pharmaceutical products